Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

2.41 Billion INR

Sector

Healthcare

Website

https://www.kilitch.com

Description

Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India.

Read More

Overview

Value

14

Growth

85

Health

36

Management

71

Analyst Opinion

80

Total

57

All Scores Out Of 100

Best Features

  • Very strong cashflow and earnings growth
  • Earnings growth has improved recently
  • Has a low level of debt
  • Low risk of bankruptcy
  • Liked by analysts
  • Has strong dividend growth
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • There is a history of diluting shareholders
  • No margin of safety at their current market price
  • Price-to-earnings ratio of 27.9 is higher than the market average (19.6x)
  • Cashflow is growing faster than revenue

Market Peers

KILITCH.NS

Key Figures

PE Ratio (TTM)

27.86

Margin Of Safety (DCF)

-61.77%

Revenue Growth (5 Year Average)

24.49%

Ratings Consensus

Buy

Share Buybacks

-4.15%

Dividend Yeild (TTM)

0.75%

Valuation

Value Score

14

  • Estimated intrinsic-value of 58.32 INR is lower than current price ( 154.65 INR)
  • Price-to-earnings ratio of 27.9 is higher than the market average (19.6x)
  • Free-cashflow-yeild of -2.84% is worse than the market average (4.7%)
  • Margin-of-safety of -61.77% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 108.8 INR

Current Price: 152.6 INR

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

27.86x

Free Cashflow Yeild

-2.84%

PE/Earnings Growth

0.28

Price/Book

1.64x

Growth

Growth Score

85

  • 5 Year Average Revenue growth of 24.49% is higher than the market average (10.97%)
  • Revenue growth has improved this yeara
  • 5 Year Average Earnings growth of 24.64% is higher than the market average (14.48%)
  • Earnings growth has improved this year
  • 5 Year Average Cashflow growth of 24.50% is higher than the market average (12.35%)
  • Free Cashflow growth has improved this year

Revenue Growth

24.49%

Earnings Growth

24.64%

Cashflow Growth

24.50%

Health

Health Score

36

  • Low risk of bankruptcy
  • Has a low level of debt
  • Assets cover liabilities
  • Low financial Leverage
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Debt repayments significantly impact cashflow

Altman Z Score

3.33

Piostroski Score

5.00

Debt/Equity

0.15x

Current Assets/Liabilities

1.65x

Free Cashflow/Total Debt

N/Ax

Debt/Capital

0.18x

Management

Management Score

71

  • Has issued new shares to finance growth when share price is high
  • Has returned higher dividends when earnings have risen
  • Return-on-capital-employed of 6.05% is lower than the market average (10%)
  • Has a history of diluting shareholders to finance activity
  • Return-on-equity of 5.25% is lower than the market average (15%)

Average Buybacks/Dilution

-4.15%

Recent Buybacks/Dilution

0.04%

5 Year Price Volitility

31.12%

Return On Assets

3.51%

Return On Capital Employed

6.05%

Return On Equity

5.25%

Return On Free Cashflow

78.74%

Return On Investments

28.27%

Analysts

Analyst Opinion

80

  • Ratings consensus is Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Kilitch Drugs (India) Limited

Currency

INR

Beta

0.340515

Vol Avg

7543

Ceo

Cik

Cusip

Y4776K110

Exchange

National Stock Exchange of India

Full Time Employees

146

Industry

Drug Manufacturers—Specialty & Generic

Sector

Healthcare

Ipo Date

1994-02-14

Address

Village: Savroli, Taluka: Khalapur, Dist: Raigad

City

Mumbai

State

MAHARASHTRA

Country

IN

Zip

400088

Phone

912261214100

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies